Using fiducial markers for targeted radiotherapy in cancer treatment
Study on the Optimal Number of Fiducial Marker Implanted With 3D-template Assitance for Stereotactic Body Radiotherapy
Peking University Third Hospital · NCT06342323
This study is testing how many fiducial markers are best to use during targeted radiotherapy for patients with lung, liver, pancreatic, and kidney cancers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 57 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking University Third Hospital (other) |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06342323 on ClinicalTrials.gov |
What this trial studies
This clinical study investigates the optimal number of fiducial markers used in stereotactic body radiotherapy (SBRT) for patients with malignant tumors, specifically lung, liver, pancreatic, and renal cancers. It is a prospective, single-center observational study aiming to enroll 15 patients for each tumor type. Participants will receive SBRT with fiducial markers implanted according to the study protocol, and their progress will be monitored throughout the treatment. Informed consent will be obtained from all participants prior to enrollment.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with lung, liver, pancreatic, or renal cell carcinoma who are scheduled to undergo SBRT.
Not a fit: Patients with anatomical challenges for needle insertion or those with poor organ function may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the precision and effectiveness of radiotherapy for various types of cancer.
How similar studies have performed: While the use of fiducial markers in SBRT has been explored, this specific approach to determining the optimal number is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with lung cancer, liver cancer, renal cancer, pancreatic cancer. * Going to have SBRT. Exclusion Criteria: * Needle insertion route impeded by skeletal structures and close to blood vessels which have high risks of puncture bleeding; * Poor organ function (e.g. poorly controlled high blood pressure); * Poor compliance, unable to complete coordination; * Participant who is considered inappropriate or unwilling to participate in this clinical trial for other reasons.
Where this trial is running
Beijing, Beijing
- Peking University Third Hospital — Beijing, Beijing, China (RECRUITING)
Study contacts
- Study coordinator: Qiu Bin, M.D.
- Email: qiubin@pku.edu.cn
- Phone: +86010-82265968
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Cancer, Liver Cancer, Pancreatic Cancer, Renal Cell Carcinoma, fiducial marker, SBRT, lung caner, liver cancer